NCT05879120View on ClinicalTrials.gov

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 30, 2024

Primary Completion Date

October 2, 2024

Study Completion Date

October 2, 2024

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Pembrolizumab

Given by IV (vein)

DEVICE

Exablate MRgFUS + neoadjuvant pembolizumab

Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

InSightec
All Listed Sponsors
collaborator

InSightec

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER